Coherus Oncology (CHRS) Stock Forecast & Price Target

$1.75 -0.04 (-2.23%)

Closing price 05/6/2026 04:00 PM Eastern

Extended Trading

$1.81 +0.06 (+3.43%)

As of 04:42 AM Eastern

Compare

Coherus Oncology - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 3 Analyst Ratings

Sell
0

Hold
1

Buy
2

Based on 3 Wall Street analysts who have issued ratings for Coherus Oncology in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a buy rating for CHRS.

Consensus Price Target

$7.00
300.00% Upside

According to the 3 analysts' twelve-month price targets for Coherus Oncology, the average price target is $7.00. The highest price target for CHRS is $10.00, while the lowest price target for CHRS is $4.00. The average price target represents a forecasted upside of 300.00% from the current price of $1.75.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CHRS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coherus Oncology and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHRS Analyst Ratings Over Time

Type	Current Forecast 5/7/25 to 5/7/26	1 Month Ago 4/7/25 to 4/7/26	3 Months Ago 2/6/25 to 2/6/26	1 Year Ago 5/7/24 to 5/7/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.00	$5.51	$5.51	$5.26
Forecasted Upside	300.00% Upside	230.09% Upside	157.59% Upside	456.17% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Moderate Buy

CHRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CHRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Coherus Oncology Stock vs. The Competition

Type	Coherus Oncology	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	300.00% Upside	913.07% Upside	14.04% Upside
News Sentiment Rating	Neutral News See Recent CHRS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/22/2026	Weiss Ratings Not Rated		Upgrade	Sell (D+) ➝ Hold (C-)
1/22/2026	Oppenheimer 3 of 5 stars	Jay Olson 4 of 5 stars	Initiated Coverage	Outperform	$10.00	+528.93%
9/4/2025	Maxim Group 1 of 5 stars	Jason McCarthy 1 of 5 stars	Upgrade	Hold ➝ Buy	$4.00	+217.46%
4/29/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$7.00 ➝ $7.00	+579.61%
4/24/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashwani Verma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$1.50 ➝ $1.05	-1.41%
12/5/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$4.00 ➝ $6.00	+250.88%
5/13/2024	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$8.00 ➝ $7.00	+258.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:00 AM ET.

CHRS Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Coherus Oncology is $7.00, with a high forecast of $10.00 and a low forecast of $4.00.
: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Oncology in the last year. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares.
: According to analysts, Coherus Oncology's stock has a predicted upside of 300.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Coherus Oncology's stock had 1 upgrade by analysts.
: Coherus Oncology has been rated by research analysts at Weiss Ratings in the past 90 days.
: Analysts like Coherus Oncology more than other "medical" companies. The consensus rating for Coherus Oncology is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CHRS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Coherus Oncology Recommendations

This page (NASDAQ:CHRS) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Stock Forecast & Price Target

Coherus Oncology - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

CHRS Analyst Ratings Over Time

CHRS Analyst Recommendations By Month

CHRS Price Targets by Month

Coherus Oncology Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

CHRS Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Coherus Oncology Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Stock Forecast & Price Target

Coherus Oncology - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

CHRS Analyst Ratings Over Time

CHRS Analyst Recommendations By Month

CHRS Price Targets by Month

Coherus Oncology Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

CHRS Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Coherus Oncology Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools